Barclays’s Amicus Therapeutics FOLD Stock Holding History

Barclays’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-114,000	Closed	-$898K	–	5380
2025 Q3	$898K	Hold	114,000	–	–	﹤0.01%	3432
2025 Q2	$653K	Sell	114,000 -32,400	-22%	-$209K	﹤0.01%	3607
2025 Q1	$1.19M	Buy	146,400 +32,400	+28%	+$300K	﹤0.01%	3002
2024 Q4	$1.07M	Hold	114,000	–	–	﹤0.01%	3335
2024 Q3	$1.22M	Buy	+114,000	New	+$1.24M	﹤0.01%	3232
2024 Q2	–	Sell	-84,800	Closed	-$999K	–	5018
2024 Q1	$999K	Buy	+84,800	New	+$1.08M	﹤0.01%	3124
2021 Q1	–	Sell	-276,500	Closed	-$6.38M	–	4863
2020 Q4	$6.38M	Buy	+276,500	New	+$5.65M	﹤0.01%	1379
2017 Q4	–	Sell	-46,800	Closed	-$706K	–	6973
2017 Q3	$706K	Buy	+46,800	New	+$619K	﹤0.01%	3306
2016 Q2	–	Sell	-88,000	Closed	-$704K	–	6406
2016 Q1	$704K	Buy	+88,000	New	+$623K	﹤0.01%	2833

Other funds holding FOLD

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Barclays's FOLD Position: Q2 2026 in Review

Barclays sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 1,338,482 shares — an estimated $19.4M sold.

Barclays first reported a position in FOLD in Q2 2013 and held it in 51 quarters. The position peaked at $19.4M in Q1 2026. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.

Barclays reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
Barclays sold 1,338,482 Amicus Therapeutics shares in Q2 2026, an estimated $19.4M.
Barclays first reported a position in Amicus Therapeutics in Q2 2013 and held it in 51 quarters.
Barclays's Amicus Therapeutics position peaked at $19.4M in Q1 2026.
2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.